Study details
Enrolling now
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
Johns Hopkins University
NCT IDNCT05836987ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
5,350
Study length
about 6.1 years
Ages
22–85
Locations
93 sites in AZ, CA, CO +26
What this study is about
Researchers are testing whether using a smart watch to guide DOAC treatment in people with atrial fibrillation reduces stroke risk compared to standard DOAC therapy. The trial will last 2210 days and involve approximately 5350 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Continuous DOAC therapy
- 2.Use AFSW Guided DOAC
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Cardiology / Heart